日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer

系统性方法确定 RHOA 是亚洲胃癌的潜在生物标志物治疗靶点

Hae Ryung Chang, Seungyoon Nam, Jinhyuk Lee, Jin-Hee Kim, Hae Rim Jung, Hee Seo Park, Sungjin Park, Young Zoo Ahn, Iksoo Huh, Curt Balch, Ja-Lok Ku, Garth Powis, Taesung Park, Jin-Hyun Jeong, Yon Hui Kim

A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells

独特的组蛋白去乙酰化酶抑制剂可改变化疗耐药卵巢癌细胞中的 microRNA 表达和信号转导

Curt Balch, Kaleb Naegeli, Seungyoon Nam, Brett Ballard, Alan Hyslop, Christina Melki, Elizabeth Reilly, Man-Wook Hur, Kenneth P Nephew

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications

卵巢肿瘤发生过程中 CLDN3 和 CLDN4 的去抑制与抑制性组蛋白修饰的丧失有关

Mi Jeong Kwon, Sung-Su Kim, Yoon-La Choi, Hun Soon Jung, Curt Balch, Su-Hyeong Kim, Yong-Sang Song, Victor E Marquez, Kenneth P Nephew, Young Kee Shin

Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells

多价表观遗传标记赋予卵巢癌细胞微环境反应的表观遗传可塑性

Sharmila A Bapat, Victor Jin, Nicholas Berry, Curt Balch, Neeti Sharma, Nawneet Kurrey, Shu Zhang, Fang Fang, Xun Lan, Meng Li, Brian Kennedy, Robert M Bigsby, Tim H M Huang, Kenneth P Nephew

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer

一种合理设计的组蛋白去乙酰化酶抑制剂,对卵巢癌具有明显的抗肿瘤活性

Ya-Ting Yang, Curt Balch, Samuel K Kulp, Michael R Mand, Kenneth P Nephew, Ching-Shih Chen